You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Drug Price Trends for NDC 00409-6637


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 00409-6637

Drug NameNDCPrice/Unit ($)UnitDate
SODIUM BICARB 8.4% ABBOJECT 00409-6637-14 0.32883 ML 2024-12-18
SODIUM BICARB 8.4% ABBOJECT 00409-6637-14 0.32883 ML 2024-10-23
SODIUM BICARB 8.4% ABBOJECT 00409-6637-14 0.32310 ML 2024-09-18
SODIUM BICARB 8.4% ABBOJECT 00409-6637-14 0.32310 ML 2024-08-21
>Drug Name>NDC>Price/Unit ($)>Unit>Date
Showing 1 to 4 of 4 entries

Best Wholesale Price for NDC 00409-6637

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug NameVendorNDCCountPrice ($)Price/Unit ($)DatesPrice Type
No data available in table
>Drug Name>Vendor>NDC>Count>Price ($)>Price/Unit ($)>Dates>Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies
Showing 0 to 0 of 0 entries

Market Analysis and Price Projections for Sodium Bicarbonate Injection (NDC: 00409-6637)

Introduction to Sodium Bicarbonate Injection

Sodium bicarbonate injection, with the NDC code 00409-6637, is a critical pharmaceutical product used in various medical settings to treat conditions such as metabolic acidosis, certain drug intoxications, and as an adjunct in severe diabetic acidosis. Here, we will delve into the market analysis and price projections for this specific product.

Market Overview

The global sodium bicarbonate injection market is influenced by several factors, including demand from hospitals, specialty clinics, and recovery centers. The market has seen significant fluctuations due to supply chain disruptions and increased demand, particularly during the COVID-19 pandemic[4].

Key Players

The market for sodium bicarbonate injection is dominated by a few key players, including Pfizer (Hospira), Amphastar, and Fresenius Kabi. Pfizer, specifically, is a major supplier of sodium bicarbonate injections in various concentrations, including the 8.4% solution with the NDC code 00409-6637[1].

Product Specifications

  • NDC Code: 00409-6637
  • Product: Sodium Bicarbonate Injection
  • Concentration: 8.4%
  • Volume: 50 mL
  • Packaging: LifeShield syringe, 10 count[1][5].

Market Trends

The demand for sodium bicarbonate injection has been on the rise due to its critical role in medical treatments. Here are some key trends:

Increased Demand

The COVID-19 pandemic has significantly increased the demand for healthcare services, including critical care medications like sodium bicarbonate injection. This surge in demand has put pressure on the supply chain, leading to occasional shortages[4].

Supply Chain Challenges

Manufacturers like Fresenius Kabi have faced challenges in maintaining production levels, leading to shortages of certain concentrations of sodium bicarbonate injection. However, other manufacturers like Amphastar and Hospira (Pfizer) have managed to keep their products available[1].

Price Projections

Current Pricing

The pricing for sodium bicarbonate injection can vary based on the supplier, volume, and the specific product code. For Medicare Part B, the Average Sales Price (ASP) is used to determine reimbursement rates. However, the ASP pricing files do not always include every product, and local contractors may determine payment amounts based on necessity and reasonableness[2].

Future Projections

According to the Vizient Pharmacy Market Outlook, the overall drug price inflation rate for 2025 is projected to be around 0%. This suggests a relatively stable pricing environment for pharmaceuticals, including sodium bicarbonate injection, in the near future[3].

Regional Market Analysis

The global market for sodium bicarbonate injection is segmented into several regions, including North America, Europe, Latin America, Asia Pacific, and the Middle East & Africa. Here’s a brief overview of the regional dynamics:

North America

This region is one of the largest markets for sodium bicarbonate injection, driven by advanced healthcare infrastructure and high demand from hospitals and specialty clinics[4].

Europe

Europe also represents a significant market, with countries like the UK, Germany, and France contributing to the demand. The region is expected to see steady growth due to increasing healthcare needs[4].

Asia Pacific

The Asia Pacific region is growing rapidly due to increasing healthcare expenditure and a rising number of hospitals and specialty clinics. Countries like India, Japan, and China are key drivers of this growth[4].

Competitive Landscape

The competitive landscape for sodium bicarbonate injection is characterized by a few dominant players. Here are some key aspects:

Market Share

Pfizer (Hospira), Amphastar, and Fresenius Kabi are among the top players in the market. Pfizer, with its comprehensive range of sodium bicarbonate injection products, holds a significant market share[1][4].

Product Differentiation

Manufacturers differentiate their products through various concentrations (e.g., 4.2%, 7.5%, 8.4%) and packaging options (e.g., syringes, vials). This differentiation helps in catering to diverse medical needs[1][5].

Challenges and Opportunities

Challenges

  • Supply Chain Disruptions: Occasional shortages due to manufacturing issues or increased demand can impact the availability of sodium bicarbonate injection.
  • Regulatory Compliance: Manufacturers must comply with stringent regulatory requirements, which can be challenging and costly[1][4].

Opportunities

  • Growing Healthcare Needs: The increasing demand for healthcare services, especially in emerging markets, presents opportunities for growth.
  • Innovative Packaging: Improvements in packaging, such as the LifeShield syringe, can enhance product safety and user convenience[1][5].

Key Takeaways

  • The global sodium bicarbonate injection market is driven by increasing healthcare needs and demand from various medical settings.
  • Key players like Pfizer (Hospira) and Amphastar dominate the market.
  • Price projections indicate a stable pricing environment for 2025.
  • Regional markets, especially North America and the Asia Pacific, are significant contributors to the global demand.
  • Supply chain disruptions and regulatory compliance are key challenges, while growing healthcare needs and innovative packaging present opportunities.

FAQs

Q: What is the NDC code for the 8.4% sodium bicarbonate injection by Pfizer? A: The NDC code for the 8.4% sodium bicarbonate injection by Pfizer is 00409-6637[1].

Q: Who are the major manufacturers of sodium bicarbonate injection? A: Major manufacturers include Pfizer (Hospira), Amphastar, and Fresenius Kabi[1].

Q: What are the projected price inflation rates for pharmaceuticals in 2025? A: According to the Vizient Pharmacy Market Outlook, the overall drug price inflation rate for 2025 is projected to be around 0%[3].

Q: How has the COVID-19 pandemic affected the demand for sodium bicarbonate injection? A: The pandemic has significantly increased the demand for healthcare services, including critical care medications like sodium bicarbonate injection, leading to occasional supply chain disruptions[4].

Q: What are the key regions driving the demand for sodium bicarbonate injection? A: North America, Europe, and the Asia Pacific are among the key regions driving the demand for sodium bicarbonate injection[4].

Sources

  1. ASHP: Drug Shortage Detail: Sodium Bicarbonate Injection.
  2. CMS: ASP Pricing Files.
  3. Vizient Inc.: Pharmacy Market Outlook Summer 2024.
  4. Reports and Data: Sodium Bicarbonate Injection Market Share, Size, Key Players, Trends, Competitive and Regional Forecast to 2027.
  5. McKesson: Sodium Bicarbonate 8.4%, 1 mEq / mL Injection 50 mL.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.